2. Search Result
Search Result
Results for "

PET

" in MedChemExpress (MCE) Product Catalog:

200

Inhibitors & Agonists

4

Fluorescent Dye

7

Biochemical Assay Reagents

28

Peptides

2

Inhibitory Antibodies

3

Natural
Products

6

Recombinant Proteins

4

Isotope-Labeled Compounds

3

Antibodies

1

Click Chemistry

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-122184
    PET-16

    		HSP Apoptosis Cancer
    PET-16 is a selective HSP70 inhibitor that binds to an allosteric pocket of the substrate-binding domain. PET-16 inhibits the ability of HSP70 to cycle between ATP-bound and ADP-bound states. PET-16 induces apoptosis in multiple myeloma .
    PET-16
  • HY-137665
    PET-cGMP

    		PKG Cardiovascular Disease
    PET-cGMP is a cyclic guanosine monophosphate analog and an effective selective agonist of PKG I, the EC50 of PET-cGMP for PKG Iβ is 3.8 nM, while for PKG II, it's 193 nM .
    PET-cGMP
  • HY-RS10338
    PET117 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    PET117 Human Pre-designed siRNA Set A contains three designed siRNAs for PET117 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PET117 Human Pre-designed siRNA Set A
    PET117 Human Pre-designed siRNA Set A
  • HY-RS10337
    PET100 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    PET100 Human Pre-designed siRNA Set A contains three designed siRNAs for PET100 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PET100 Human Pre-designed siRNA Set A
    PET100 Human Pre-designed siRNA Set A
  • HY-137378A
    8-Br-PET-cGMP

    		PKG Cardiovascular Disease Inflammation/Immunology
    8-Br-PET-cGMP is an agonist of cGMP-dependent protein kinase type I (cGKI). 8-Br-PET-cGMP promotes the dimerization of cGKI and activates its catalytic activity by binding to the regulatory domain of cGKI. 8-Br-PET-cGMP can be used to study the role of cGMP signaling pathways in cell growth, vasodilation, and smooth muscle cell function .
    8-Br-PET-cGMP
  • HY-108548
    Rp-8-Br-PET-cGMPS sodium

    Rp-8-Bromo-PET-cGMPS

    		 PKG Inflammation/Immunology
    Rp-8-Br-PET-cGMPS sodium (Rp-8-Bromo-PET-cGMPS) is an analog of cyclic GMP (cGMP). It is a cell permeable, competitive, and reversible inhibitor of cGMP-dependent protein kinases (cGKs) that blocks activation of cGKI and cGKII by cGMP (Kis=35 and 30 nM). It less potently inhibits protein kinase A (Ki=11 μM) and cGMP-induced activation of cyclic nucleotide-gated channels (IC50=25 μM). In the absence of cGMP stimulation, Rp-8-bromo-PET-cGMPS can act as a partial agonist of cGKI (Ki=1 μM). Rp-8-bromo-PET-cGMPS is resistant to hydrolysis by phosphodiesterase 11.
    Rp-8-Br-PET-cGMPS sodium
  • HY-155741
    CB2 PET Radioligand 1

    		Cannabinoid Receptor Neurological Disease
    CB2 PET Radioligand 1 (compound [18F]9) is a PET Radioligand targeting to hCB2 (Ki=7.7 nM). CB2 PET Radioligand 1 is prepared with Cu-mediated 18F-fluorination. CB2 PET Radioligand 1 shows high brain uptake in a murine model of neuroinflammation .
    CB2 PET Radioligand 1
  • HY-137629
    Sp-8-pCPT-PET-cGMPS

    		PKG Cardiovascular Disease
    Sp-8-pCPT-PET-cGMPS is an activator for PKG-I. Sp-8-pCPT-PET-cGMPS can be used for research of NO/NOS/sGC/PKG-I signaling pathway in cardiac differentiation .
    Sp-8-pCPT-PET-cGMPS
  • HY-137633
    Sp-8-Br-PET-cGMPS

    		PKG Neurological Disease
    Sp-8-Br-PET-cGMPS is a membrane-permeable PKG agonist and a membrane-permeable inhibitor of retinal-type cGMP-gated ion channels, as well as an activator of cGMP-dependent protein kinases I α and I β. Sp-8-Br-PET-cGMPS is resistant to mammalian cyclic nucleotide-dependent phosphodiesterases, has no metabolic side effects, and is more lipophilic and permeable than Sp-8-pCPT-cGMPS. Sp-8-Br-PET-cGMPS can be used to study the role of cGMP signaling pathways in the nervous system .
    Sp-8-Br-PET-cGMPS
  • HY-W700684
    N-Didesmethyl Loperamide

    R 21345

    		 Drug Metabolite Others
    N-Didesmethyl Loperamide is a metabolite of Loperamide; a new and improved PET radiotracer for imaging P-gp function.
    N-Didesmethyl Loperamide
  • HY-168343
    Ga-DOTA-Olmutinib

    		Biochemical Assay Reagents Cancer
    Ga-DOTA-Olmutinib is a potential PET tracer designed to detect EGFR-positive cancers .
    Ga-DOTA-Olmutinib
  • HY-159001
    ZCDD083

    		Biochemical Assay Reagents Others
    ZCDD083 can be used as a positron emission tomography (PET) tracer for atherosclerotic plaques imagination, when labeled with 18F isotope .
    ZCDD083
  • HY-175748
    MK-7337

    		α-synuclein Neurological Disease
    MK-7337 is an α-synuclein PET ligand. MK-7337 labeled with 11C can be used as a PET tracer for neurodegenerative disorders like Parkinson’s disease imagination .
    MK-7337
  • HY-168647
    KAC-50.1

    		α-synuclein Neurological Disease
    KAC-50.1 is an α-Synuclein (α-syn) PET ligand, with a KD of 35 nM toward site 2 in recombinant α-syn fibrils .
    KAC-50.1
  • HY-100275
    MK-3328

    		Amyloid-β Neurological Disease
    MK-3328 is a β-Amyloid ligand, which exhibits high binding potency with an IC50 of 10.5 nM. MK-3328 is capable of being labelled with 18F for positron emission tomography (PET) imaging .
    MK-3328
  • HY-135497
    Fallypride

    		Dopamine Receptor Neurological Disease
    Fallypride is a potent antagonist of dopamine D2/D3 receptor. Fallypride, in the form of fallypride ( 18F), can be used as a positron emission tomography (PET) radiotracer .
    Fallypride
  • HY-158326
    FAP-IN-4

    		FAP Cancer
    FAP-IN-4 (Comp 10) is a fibroblast activation protein (FAP) inhibitor and a 18F-labeled PET tracer targeting FAP. FAP-IN-4 can be used for cancer research .
    FAP-IN-4
  • HY-W074537
    P7-2104

    		Phosphodiesterase (PDE) Neurological Disease
    P7-2104 is a cyclic nucleotide phosphodiesterase 7 (PDE7) inhibitor, with IC50 at 31 nM. P7-2104 can be labeled with C-11 for PET neuroimaging research .
    P7-2104
  • HY-177459
    DOTA-2P(FAPI)2

    		FAP Cancer
    DOTA-2P(FAPI)2 is a dimeric FAP (fibroblast activation protein) that can be used as a PET imaging agent and a tracer for tumor therapy .
    DOTA-2P(FAPI)2
  • HY-155483
    PSMA-BCH

    NOTA-PSMA

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    PSMA-BCH (NOTA-PSMA) is a NOTA-conjugated precursor. NOTA is a bifunctional chelate which acts as the framework to construct PET imaging tools .
    PSMA-BCH
  • HY-D2343
    PB0822

    		Biochemical Assay Reagents Neurological Disease
    PB0822 can be used for in vivo PET imaging when labeled with [ 18F]fluoride. [ 18F]PB0822 is a PET radioligand. [ 18F]PB0822 has a cLogP value of 1.54, which is a good predictive index for BBB penetration. [ 18F]PB0822 can be used for Alzheimer’s Disease research .
    PB0822
  • HY-P10307
    DOTA-ubiquicidin (29–41)

    		Radionuclide-Drug Conjugates (RDCs) Bacterial Infection
    DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ 68Ga]Ga-DOTA-Ubiquicidin29-41 and then used for imaging of infectious processes using PET/CT . DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-ubiquicidin (29–41)
  • HY-W792458
    MADAM

    		Serotonin Transporter Neurological Disease
    MADAM exhibits high affinity and selectivity for 5-HTT with a Ki value of 1.6 nM. MADAM has the potential to serve as a PET radiotracer for visualizing the serotonin transporter .
    MADAM
  • HY-P11287
    DOTA-Pep-1L

    		Interleukin Related Cancer
    DOTA-Pep-1L is a peptide conjugated with DOTA and Pep-1L, a peptide that specifically targets the IL13RA2 receptor. DOTA-Pep-1L can be used for PET imaging and tumor-targeted therapy research .
    DOTA-Pep-1L
  • HY-W539893
    NODAGA-tris(t-Bu ester)

    NODAG

    		 Biochemical Assay Reagents Cancer
    NODAGA-tris(t-Bu ester) (NODAG) is a NODAGA derivative. NODAGA-tris(t-Bu ester) can be used to label peptides, antibodies, etc., and subsequently radiolabeled for PET imaging .
    NODAGA-tris(t-Bu ester)
  • HY-P11287A
    DOTA-Pep-1L TFA

    		Interleukin Related Cancer
    DOTA-Pep-1L TFA is a peptide conjugated with DOTA and Pep-1L, a peptide that specifically targets the IL13RA2 receptor. DOTA-Pep-1L TFA can be used for PET imaging and tumor-targeted therapy research .
    DOTA-Pep-1L TFA
  • HY-149869
    PSMA-IN-3

    		PSMA Cancer
    PSMA-IN-3 (compound 17) is a novel high-affinity PSMA inhibitor with an IC50 value of 13 nM. PSMA-IN-3 is suitable for developing an 18F-labeled radioligand for PET imaging of PSMA in prostate cancer .
    PSMA-IN-3
  • HY-136404
    Melanin probe-1

    		Fluorescent Dye Cancer
    Melanin probe-1 is an 18F-picolinamides based PET probe. Melanin probe-1 can be used for PET imaging of malignant melanoma. Melanin probe-1 exhibits high tumor targeting efficiency, excellent tumor imaging contrasts, desirable biodistribution patterns, and good in vivo stability .
    Melanin probe-1
  • HY-174977
    P2Y12R ligand-1

    		P2Y Receptor Neurological Disease
    P2Y12R ligand-1 (Compound 41) is a high-affinity P2Y12R ligand with a Ki value of 17.1 nM. P2Y12R ligand-1 labeled with [ 18F] can be used in studies of brain PET imaging .
    P2Y12R ligand-1
  • HY-W755222
    (S)-NODAGA-tris(t-Bu ester)

    (S)-NODAG

    		 Biochemical Assay Reagents Cancer
    (S)-NODAGA-tris(t-Bu ester) ((S)-NODAG) is a NODAGA derivative. (S)-NODAGA-tris(t-Bu ester) can be used to label peptides, antibodies, etc., and subsequently radiolabeled for PET imaging .
    (S)-NODAGA-tris(t-Bu ester)
  • HY-W591317
    (R)-NODAGA-tris(t-Bu ester)

    (R)-NODAG

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    (R)-NODAGA-tris(t-Bu ester) ((R)-NODAG) is a NODAGA derivative. (R)-NODAGA-tris(t-Bu ester) can be used to label peptides, antibodies, etc., and subsequently radiolabeled for PET imaging .
    (R)-NODAGA-tris(t-Bu ester)
  • HY-157556
    BPP-2

    		GHSR Others
    BPP-2 is a GHSR ligand with an F element. Using 18F isotope labeling BPP-2, a PET probe targeting GHSR can be obtained. The binding affinity Ki of 18F-BPP-2 for GHSR is 274 nM .
    BPP-2
  • HY-P5362
    NODAGA-LM3

    		Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Cancer
    NODAGA-LM3 can be labeled by 68Ga for PET imaging. 68Ga-NODAGA-LM3 is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas. NODAGA-LM3 can be labeled with [68Ga] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    NODAGA-LM3
  • HY-158317
    SFB-AMD3465

    		CXCR Biochemical Assay Reagents Others
    SFB-AMD3465 is an AMD3465 (HY-15971A) derivative. SFB-AMD3465 is utilized as positron emission tomography (PET) tracer for CXCR4, when labeled with radioactive Fluorine .
    SFB-AMD3465
  • HY-P5362A
    NODAGA-LM3 TFA

    		Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Cancer
    NODAGA-LM3 TFA can be labeled by 68Ga for PET imaging. 68Ga-NODAGA-LM3 TFA is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas. NODAGA-LM3 TFA can be labeled with [68Ga] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    NODAGA-LM3 TFA
  • HY-100705
    DMNB

    6-Nitroveratraldehyde

    		 Drug Intermediate Neurological Disease
    DMNB (6-Nitroveratraldehyde), a precursor, can be used for the synthesis no-carrier-added 6-[ 18F]fluoro-L-DOPA (6-FDOPA). No-Carrier-Added (NCA) 6-[18F]fluoro-L-dopa (6-FDOPA) is being produced routinely for PET investigations of dopaminergic systems .
    DMNB
  • HY-D2334
    AlF-NOTA-c-d-VAP

    		Radionuclide-Drug Conjugates (RDCs) HSP Cancer
    AlF-NOTA-c-d-VAP is a peptide positron emission tomography (PET) probe that used for targeted tumor imaging of GRP78. AlF-NOTA-c-d-VAP demonstrates high stability in vitro and in vivo .
    AlF-NOTA-c-d-VAP
  • HY-175229
    PSMA ligand 1

    		PSMA Cancer
    PSMA ligand 1 (Compound 1c) is a PSMA ligand with an IC50 of 26.74 nM. The [ 18F]-labeled PSMA ligand 1 can serve as a PSMA PET tracer and is used in research on the diagnosis of prostate cancer .
    PSMA ligand 1
  • HY-153549
    Pentixafor

    		Radionuclide-Drug Conjugates (RDCs) CXCR Others
    Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with 68Gallium ( 68Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Pentixafor
  • HY-172365
    P7–2302

    		Phosphodiesterase (PDE) Inflammation/Immunology
    P7-2302 inhibits PDE7 and PDE4B with IC50 of 0.18 nM and 77.3 nM. P7-2302 inhibits the efflux of P-gp and BCRP (breast cancer resistance protein), exhibits low uptake in rats brain. P7-2302 can be used as a PET tracer when labeled with 18F .
    P7–2302
  • HY-167899
    PXT-012253

    		mGluR Neurological Disease
    PXT-012253 is a positron emission tomography (PET) ligand for mGluR4, as it binds to an allosteric site on mGluR4. PXT-012253 can be utilized in researches related to Parkinson's disease and levodopa-induced dyskinesia .
    PXT-012253
  • HY-107531
    A 1070722

    		GSK-3 Neurological Disease Cancer
    A 1070722 is a potent and selective glycogen synthase kinase 3 (GSK-3) inhibitor, with a Ki of 0.6 nM for both GSK-3α and GSK-3β. A 1070722 can penetrate the blood-brain barrier (BBB) and accumulates in brain regions, thus potential for PET radiotracer for the quantification of GSK-3 in brain. A 1070722 decreases spontaneous locomotion .
    A 1070722
  • HY-161246
    uPSEM792

    		5-HT Receptor Neurological Disease
    uPSEM792 is a pharmacologically selective effector molecules (PSEM) agonist for PSAM 4-GlyR, with an affinity of Ki of 0.7 nM. uPSEM792 is a substrate for efflux transporters in brains of wild type and dual P-gp and BCRP knockout mice. uPSEM7952 is a possible lead for developing the PET radioligand for PSAM 4-GlyR .
    uPSEM792
  • HY-149766
    PB94

    		HDAC Neurological Disease
    PB94 is a selective HDAC11 inhibitor (IC50=108 nM). PB94 can be radiolabeled as [11C]-PB94 for use in positron emission tomography (PET), as well as brain uptake and metabolic properties in administered live animals. PB94 improves neuropathic pain in mice and could be used to study neurological indications .
    PB94
  • HY-175685
    FAP-IN-7

    		FAP Cancer
    FAP-IN-7 (Compound 5b) is a FAP18F enhances tumor retention with high selectivity and favorable pharmacokinetics. FAP-IN-7 can be used as a radiotracer for PET imaging and radionuclide therapy of cancers research .
    FAP-IN-7
  • HY-152152
    JZP-MA-13

    		MAGL Neurological Disease
    JZP-MA-13 is a selective α/β-hydrolase domain 6 (ABHD6) inhibitor with an IC50 of 392 nM. JZP-MA-13 shows no inhibition of MAGL, ABHD12, FAAH, or other serine hydrolases. JZP-MA-13 is a positron emission tomography (PET) ligand for in vivo imaging of the ABHD6 .
    JZP-MA-13
  • HY-174923
    AZ12943203

    		Biochemical Assay Reagents GSK-3 Neurological Disease
    AZ12943203 (Compound 13e) is a GSK-3 PET radioligand with a Kd of 2.94  nM. AZ12943203 has a significant inhibitory potency toward GSK-3β (IC50 : 4.44 nM), and can specifically bind to GSK-3-rich regions of the rodent brain. AZ12943203 can be used for neurodegenerative diseases imaging, particularly Alzheimer’s disease .
    AZ12943203
  • HY-W728451
    URB694

    		FAAH Cardiovascular Disease Neurological Disease
    URB694 is a carbamate FAAH inhibitor that irreversibly carbamoylate the nucleophile catalytic serine in FAAH active site. URB694 exhibits antidepressant-like activity and cardioprotective effects. URB694 can be used to prepare 11C-Carbonyl-URB694 for in vivo positron emission tomography (PET) imaging studies of the brain FAAH .
    URB694
  • HY-162574
    CYP11B2-IN-2

    		Cytochrome P450 Cancer
    CYP11B2-IN-2 (Compound 10k) is an inhibitor for enzyme aldosterone synthase CYP11B2 with an IC50 of 0.3 nM. CYP11B2-IN-2 CYP11B-IN-2 is labeled with 18F and can be used as a positron emission tomography (PET) tracer for the diagnosis of primary aldosteronism .
    CYP11B2-IN-2
  • HY-119190
    PF-06445974

    		Phosphodiesterase (PDE) Neurological Disease
    PF-06445974, a promising positron emission tomography (PET) lead, has exquisite potency at PDE4B with an IC50 <1 nM. The IC50 values are 36, 4.7 and 17 nM for PDE4D, PDE4A and PDE4C, respectively. PF-06445974 has good selectivity over PDE4D, excellent brain permeability, and a high level of specific binding in the "cold tracer" study .
    PF-06445974

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: